×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TAK – takeda pharmaceutical company limited american depositary shares (each representing 1/2 of a share of) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TAK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/28
07:12 am
tak
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
Low
Report
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
11/25
01:57 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
11/18
01:21 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
Neutral
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
11/12
01:30 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
11/8
07:05 pm
tak
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
11/7
11:00 am
tak
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Low
Report
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
11/6
08:22 am
tak
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
Low
Report
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
11/3
07:00 am
tak
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Low
Report
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/5
06:08 am
tak
Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
Low
Report
Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
12/4
06:04 am
tak
Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
Low
Report
Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
11/28
06:09 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Nov 28
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Nov 28
11/13
07:58 am
tak
Form 13F-HR TAKEDA PHARMACEUTICAL For: Sep 30
Low
Report
Form 13F-HR TAKEDA PHARMACEUTICAL For: Sep 30
10/30
06:13 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
10/30
06:08 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
10/30
06:08 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
10/1
09:23 am
tak
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 01
Low
Report
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 01
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
5.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
4/6 European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC 4.9%
7/31 Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration 4.9%
3/4 Takeda Completes Sale of Select OTC and Non-Core Assets to STADA 4.8%
4/10 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 4.1%
5/9 Asia Markets: Asian markets mostly gain despite looming U.S. tariff hikes targeting Chinese goods [MarketWatch] 4.1%
11/1 Takeda Pharmaceutical Co. Ltd (TKPHF) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.8%
4/27 Takeda ProThera Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 3.8%
2/4 Japan's Takeda forecasts surprise full-year operating profit [Yahoo! Finance News] 3.2%
5/17 Canadian Blood Services warns of imminent shortage of take-home immune globulin drug [Toronto Globe and Mail (Ontario, Canada)] 3.1%
TOP News Decliners
3/17
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
-10.1%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
5/14 Takeda forecasts operating loss as Shire integration costs mount [FT.com - Mergermarket] -8.0%
2/26 Form POS AM TAKEDA PHARMACEUTICAL -6.6%
10/21 Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease -5.0%
11/9 2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now [The Motley Fool] -4.0%
5/16 Takeda Pharmaceutical Co Ltd (NYSE: TAK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.6%
11/8 New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period -3.6%
7/9 Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index -3.0%
3/4 Japan's Takeda Pharma says it is developing coronavirus drug [Reuters (UK)] -2.7%
3/4 Japan stocks track Wall Street higher, but virus worries weigh [Reuters] -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: